Wedbush Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsDowngradesPrice Target
Wedbush analyst David Nierengarten downgrades TScan Therapeutics (NASDAQ:TCRX) from Outperform to Neutral and lowers the price target from $5 to $1.
Wedbush analyst David Nierengarten downgrades TScan Therapeutics (NASDAQ:TCRX) from Outperform to Neutral and lowers the price target from $5 to $1.